Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Forchhammer

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Virchows Archiv : an International Journal of Pathology|June 18, 2024
Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control studyStephan Forchhammer, Oltin Tiberiu Pop, Matthias Hahn, et al.
Journal of the American Academy of Dermatology|July 24, 2023
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapyTeresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, et al.
Journal for Immunotherapy of Cancer|December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapyJonas Bochem, Henning Zelba, Janine Spreuer, et al.
The British Journal of Dermatology|March 4, 2025
Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomasMariantonia Costanza, Catello Giordano, Ann-Christin von Brünneck, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 14, 2022
Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERD<sub>ND</sub> ): Time to Move Beyond the SkinIsabell Cordts, Demet Önder, Andreas Traschütz, et al.
Ebiomedicine|September 16, 2023
UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescentsAlexandra Liebmann, Jakob Admard, Sorin Armeanu-Ebinger, et al.
Molecular Cancer|December 16, 2023
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumorsPhilipp Knopf, Dimitri Stowbur, Sabrina H L Hoffmann, et al.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Nature Communications|July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 yearsClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteerHans-Georg Rammensee, Karl-Heinz Wiesmüller, P Anoop Chandran, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Virchows Archiv : an International Journal of Pathology|June 18, 2024
Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control studyStephan Forchhammer, Oltin Tiberiu Pop, Matthias Hahn, et al.
Journal of the American Academy of Dermatology|July 24, 2023
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapyTeresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, et al.
Journal for Immunotherapy of Cancer|December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapyJonas Bochem, Henning Zelba, Janine Spreuer, et al.
The British Journal of Dermatology|March 4, 2025
Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomasMariantonia Costanza, Catello Giordano, Ann-Christin von Brünneck, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 14, 2022
Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERD<sub>ND</sub> ): Time to Move Beyond the SkinIsabell Cordts, Demet Önder, Andreas Traschütz, et al.
Ebiomedicine|September 16, 2023
UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescentsAlexandra Liebmann, Jakob Admard, Sorin Armeanu-Ebinger, et al.
Molecular Cancer|December 16, 2023
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumorsPhilipp Knopf, Dimitri Stowbur, Sabrina H L Hoffmann, et al.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Nature Communications|July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 yearsClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteerHans-Georg Rammensee, Karl-Heinz Wiesmüller, P Anoop Chandran, et al.
Pageof 7